Public Calendar: March 15-21, 2020
This public calendar is issued by the Food and Drug Administration. It lists significant meetings held by designated FDA policy makers with persons outside the executive branch of the federal government.
Official Name: Stephen M. Hahn, M.D., Commissioner of Food and Drugs
Event Date: 03/17/2020
Location: Teleconference
Subject: Advanced Medical Technology Association Board Meeting: Contain the Spread of COVID-19
FDA Participant/Group: N/A
Non FDA Participant/Group: Several board members from Advanced Medical Technology Association
Official Name: Amy Abernethy, M.D., Ph.D, Principal Deputy Commissioner
Event Date: 03/19/2020
Location: Virtual
Subject: CBD Working Group Listening Session with Epilepsy Foundation
FDA Participant/Group: PATRICK COURNOYER; SHARON MAYL; APRIL ALEXANDROW; DOUGLAS THROCKMORTON; SHERENE SEPEHRI; LOWELL SCHILLER; JOSEPH FRANKLIN; MELISSA ROBB;
Non FDA Participant/Group: Abbey Roudebush, Brandy Fureman, Jacqueline French, Laura Weidner (Epilepsy Foundation );
Official Name: Anand Shah, M.D., Deputy Commissioner for Medical and Scientific Affairs
No Significant Event
Official Name: Anna Abram, Deputy Commissioner for Policy, Legislation, and International Affairs
No Significant Event
Official Name: Jim Sigg, Deputy Commissioner for Operations
No Significant Event
Official Name: Frank Yiannas, Deputy Commissioner for Food Policy and Response
Event Date: 03/18/2020
Location: Virtual
Subject: Food Safety Issues in Response to COVID-19 Outbreak
FDA Participant/Group: Several Senior FDA Officials and Staff
Non FDA Participant/Group: Several representatives from the food industry, government, and academia
Event Date: 03/19/2020
Location: Virtual
Subject: Food Safety Issues in Response to COVID-19 Outbreak
FDA Participant/Group: LEEANNE JACKSON; NINA ZIMDAHL; CAITLIN BOON;
Non FDA Participant/Group: Several executives from the food and beverage industry
Official Name: Lowell Schiller, Principal Associate Commissioner for Policy
Event Date: 03/19/2020
Location: Silver Spring, MD
Subject: Listening Session with the Epilepsy Foundation
FDA Participant/Group: DOUGLAS THROCKMORTON; AMY ABERNETHY; JOSEPH FRANKLIN; SHARON MAYL; APRIL ALEXANDROW; MELISSA ROBB; SHERENE SEPEHRI; PATRICK COURNOYER;
Non FDA Participant/Group: Abbey Roudebush, Brandy Fureman, Jacqueline French, Laura Weidner (Epilepsy Foundation );
Official Name: Mark Abdoo, Associate Commissioner for Global Policy and Strategy
No Significant Event
Official Name: Judy McMeekin, Acting Associate Commissioner for Regulatory Affairs
No Significant Event
Official Name: Laura Caliguiri, Associate Commissioner for External Affairs
No Significant Event
Official Name: RADM Denise Hinton, Chief Scientist
No Significant Event
Official Name: Janet Woodcock, M.D., Director, Center for Drug Evaluation and Research
No Significant Event
Official Name: Peter Marks, M.D., Ph.D., Director, Center for Biologics Evaluation and Research
No Significant Event
Official Name: Jeffrey Shuren, M.D., J.D., Director, Center for Devices and Radiological Health
No Significant Event
Official Name: Susan T. Mayne, Ph.D., Director, Center for Food Safety and Applied Nutrition
No Significant Event
Official Name: Mitchell R. Zeller, J.D., Director, Center for Tobacco Products
No Significant Event
Official Name: Steven Solomon, Director, Center for Veterinary Medicine
No Significant Event
Official Name: William Slikker, Jr., Ph.D., Director, National Center for Toxicological Research
No Significant Event
Official Name: Stacy Cline Amin, Chief Counsel
No Significant Event